Omkar Pharmachem Ltd reported a net profit of ₹12.18 lakh for FY26, a decline from ₹20.09 lakh in the previous year. Total income for the period ended March 31, 2026, stood at ₹47.24 lakh, down from ₹54.22 lakh in FY25.

The company submitted its 31st Annual General Meeting (AGM) notice and annual report to the Bombay Stock Exchange on September 2, 2026. The AGM is scheduled for September 30, 2026, at Hotel Kanak in Ahmedabad.

Financial Performance

Revenue from operations decreased to ₹46.50 lakh from ₹54.00 lakh in FY25. Employee benefit expenses rose to ₹20.86 lakh from ₹16.07 lakh, while finance costs dropped significantly to ₹0.21 lakh from ₹1.71 lakh due to loan repayment. Other expenses increased slightly to ₹9.56 lakh from ₹8.93 lakh.

Balance Sheet Highlights

Total assets grew to ₹3,669.04 lakh from ₹960.33 lakh, primarily driven by an increase in non-current investments to ₹3,638.43 lakh from ₹930.00 lakh. This revaluation created a Fair Value Through Other Comprehensive Income (FVTOCI) reserve of ₹2,708.43 lakh. The company closed the year with zero borrowings, having repaid its ₹11.85 lakh outstanding debt from FY25. Cash and cash equivalents rose to ₹21.73 lakh from ₹10.94 lakh.

What the Numbers Show

The sharp increase in total assets is not operational but accounting-driven. While operational revenue declined by 15%, total equity surged to ₹3,663.98 lakh from ₹943.37 lakh solely due to the ₹2,708.43 lakh unrealized gain on unlisted equity investments. This masks the underlying operational contraction, where net profit margins fell from 37% to 26% as fixed costs remained elevated despite lower sales volumes.

AGM Agenda and Logistics

The AGM will address three key items:

• Adoption of audited financial statements for FY26.
• Re-appointment of Mr. Parminder Sharma, who retires by rotation.
• Approval of material related-party transactions involving remuneration for Key Managerial Personnel (KMPs), specifically the Company Secretary and CFO, valued up to ₹25 lakh for FY27.

Shareholders holding shares as of the record date, September 23, 2026, are eligible to vote. Remote e-voting via Central Depository Services (India) Limited will be open from September 27 to September 29, 2026.

Omkar Pharmachem reported a net loss of ₹1.00 lakh for the quarter ended June 30, 2026, marking a shift from the ₹1.50 lakh profit recorded in the immediately preceding quarter ended March 31, 2026. The Board of Directors approved the unaudited standalone financial results on August 13, 2026. The results were reviewed by the audit committee and in accordance with Standard on Review Engagement (SRE) 2410 by Dipal R. Shah & Co., Chartered Accountants.

The company generated zero income from core operations, with net sales remaining at nil. Total income from operations was confined to ₹9.00 lakh from other operating income, which remained stable compared to the prior quarter but fell from ₹13.50 lakh in the same period last year. Other income was nil for the current quarter, compared to ₹0.30 lakh in the previous quarter.

Financial Performance

Total expenses increased to ₹10.00 lakh from ₹7.35 lakh in the previous quarter. This rise was largely attributable to an increase in other expenses, which jumped to ₹4.82 lakh from ₹2.13 lakh. Employee benefits remained steady at ₹5.14 lakh, while depreciation and amortization costs decreased slightly to ₹0.04 lakh from ₹0.08 lakh. There were no exceptional items or tax expenses reported for the quarter.

What the Numbers Show

The financial data reveals a complete absence of operational revenue generation during the quarter. With net sales at zero, the company’s ability to cover fixed costs relied entirely on non-operating income streams. The widening loss despite stable other operating income highlights the pressure from variable other expenses, which more than doubled compared to the previous quarter, eroding the thin margin previously supported by lower cost structures.